Subjects intended to be treated with Serranator® for de-novo or restenotic lesions of the iliac, femoral, iliofemoral, popliteal, infrapopliteal and pedal arteries or dysfunctional native or synthetic arteriovenous dialysis fistulae.
Subjects presenting with claudication or critical limb-threatening ischemia (CLTI) by Rutherford Clinical Category 3, 4, 5, or 6 of the target limb.
Age of subject is \> 18.
Subject or subject's legal representative has been informed of the nature of the study, agrees to participate and has signed the approved consent form.
You may not be if
Subjects with any medical condition that would make him/her an inappropriate candidate for treatment with Serranator® as per Instructions for Use (IFU) or investigator's opinion.
Subject already enrolled in other investigational (interventional) studies that would interfere with study endpoints.
